SecBot SecBot
8-K ·Filed Apr 21, 2026

DGX

QUEST DIAGNOSTICS INC
BULLISH
Impact 8/10
Horizondays Processed6mo ago SEC0001022079-26-000040
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of revenue beat, EPS beat, and raised guidance suggests strong underlying momentum; monitor upcoming quarters for sustainability of organic volume growth and margin expansion.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$205.04
T+0 close · Apr 21, 2026 · via day close
Latest settled
+2.13%
T+60 · $209.41
Vs SPY
−4.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $205.04entry
  2. T+1 · 7mo ago −0.51%α −1.53% · $204.00
  3. T+5 · 7mo ago −4.87%α −5.96% · $195.05
  4. T+20 · 6mo ago −7.41%α −12.33% · $189.84
  5. T+60 · 4mo ago +2.13%α −4.77% · $209.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Quest Diagnostics reported strong Q1 2026 results with revenue of $2.90 billion (up 9.2% YoY) and reported EPS of $2.24 (up 15.5% YoY), beating consensus. The company raised full-year 2026 EPS guidance, signaling confidence in sustained growth from organic volume expansion and operational execution.

Key Financial Metrics

EPS
$2.24
est $2.37 · -5.5%
Revenue
$2.9B
est $2.8B · +2.5% · +9.2% YoY
Rating
beat
Guidance
$11.78B-$11.90B
raised

Key Facts

  • Q1 2026 revenue was $2.90 billion, up 9.2% YoY with 9.0% organic growth
  • Reported diluted EPS was $2.24, up 15.5% YoY; adjusted EPS was $2.50, up 13.1% YoY
  • Company raised full-year 2026 adjusted EPS guidance to $10.63–$10.83 (from $10.50–$10.70)

Financial Impact

Revenue increased $250 million and EPS increased $0.30 YoY, with guidance raised above prior expectations

revenueepsoperating_income

Risk Factors

  • Guidance raise depends on continued execution of Project Nova and Co-Lab integrations
  • Exposure to reimbursement policy changes in clinical laboratory testing

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001022079-26-000040
Document: dgx-20260421.htm0001022079-26-000040
Document: 0001022079-26-000040-index-headers.html0001022079-26-000040
Document: 0001022079-26-000040-index.html0001022079-26-000040
Document: 0001022079-26-000040.txt0001022079-26-000040
8-K Data (Synthetic)0001022079-26-000040

US Market Status

Market Open · Closes in 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026